Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleResearchers from the University of East Anglia and Oxford Biodynamics have developed the first-ever blood test for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). The new test, utilising EpiSwitch 3D Genomics technology, identifies unique DNA folding patterns in blood samples of ME/CFS patients, achieving 92 per cent sensitivity and 98 per cent specificity. This breakthrough offers the potential for a simple, accurate diagnosis, which could lead to earlier support, more effective management, and the development of targeted treatments for the condition. Currently, ME/CFS is diagnosed based on symptoms, often leading to years of undiagnosed or misdiagnosed cases, with over 400,000 people in the UK estimated to be affected. While experts welcome the development, they call for further independent studies to validate the findings across a wider patient population and to assess its differentiation from other conditions with similar symptoms. In fullScientists develop first-ever blood test to diagnose METhank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Chronic fatigue breakthrough as diagnostic blood test developed
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleResearchers from the University of East Anglia and Oxford Biodynamics have developed the first-ever blood test for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). The new test, utilising EpiSwitch 3D Genomics technology, identifies unique DNA folding patterns in blood samples of ME/CFS patients, achieving 92 per cent sensitivity and 98 per cent specificity. This breakthrough offers the potential for a simple, accurate diagnosis, which could lead to earlier support, more effective management, and the development of targeted treatments for the condition. Currently, ME/CFS is diagnosed based on symptoms, often leading to years of undiagnosed or misdiagnosed cases, with over 400,000 people in the UK estimated to be affected. While experts welcome the development, they call for further independent studies to validate the findings across a wider patient population and to assess its differentiation from other conditions with similar symptoms. In fullScientists develop first-ever blood test to diagnose METhank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
